A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

NCT00989001 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Vernakalant
DRUG: Placebo

Sponsor

Advanz Pharma